Frederick "Rick" Jones
Dr. Frederick “Rick” Jones is a life science investor, entrepreneur and physician with extensive experience in biopharmaceuticals and healthcare.
Before joining BioAdvance, Rick was a Director at Broadview Ventures, a philanthropic venture investor with a mission to support early stage companies with potential breakthrough technologies in cardiovascular disease. At Broadview he participated in all aspects of the investment process including sourcing opportunities, diligence, negotiating deal terms, supporting portfolio companies and serving on corporate boards.
Before Broadview, Rick held a variety of roles in startup and medium sized biotech companies. He was CEO of Anchor Therapeutics, a company with a lipidated peptide platform technology to modulate refractory GPCR targets. Earlier, he was head of the pharma business unit at Devgen, a Belgian biotechnology company. Rick started his biotech career as Vice President of Business Development at BioRexis, a company with a platform technology to extend the half-life of peptides, where he participated in the successful sale of the company to Pfizer. Preceding his biotech positions, Rick worked in big pharma at Wyeth Pharmaceuticals, where he held positions in Global Business Development and Global Medical Affairs.
Rick began his career as an internal medicine physician, most recently as Assistant Professor Clinical Medicine in the University of Pennsylvania Health System. Prior to that he was on staff at the Lahey Clinic and served in the Naval Medical Corps at Long Beach Naval Hospital. Rick received his BA, MD and MBA degrees from the University of Pennsylvania.